Treace Medical Concepts will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Quiver AI Summary
Treace Medical Concepts, Inc. has announced that CEO John T. Treace will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Treace Medical is focused on advancing the surgical treatment of bunions and midfoot deformities, which affect about 67 million Americans. The company has developed the patented Lapiplasty® 3D Bunion Correction® System, addressing the root causes of bunions with innovative surgical methods. They also offer additional products for midfoot deformities and minimally invasive procedures, and are expanding their technology and services in the market. A live webcast of the presentation will be available on their investor relations website, and Treace encourages individuals to regularly check their website for updates and important information.
Potential Positives
- Treace Medical Concepts is set to present at the prestigious 44th Annual J.P. Morgan Healthcare Conference, which may enhance visibility and credibility in the medical technology sector.
- The company highlights its innovative and patented Lapiplasty® 3D Bunion Correction® System, showcasing its commitment to advanced surgical solutions and addressing a significant medical need affecting millions.
- Treace's ongoing expansion of its product offerings, including various advanced systems for surgical correction, positions the company well for growth in the healthcare market.
Potential Negatives
- None
FAQ
What is Treace Medical Concepts, Inc.?
Treace Medical Concepts, Inc. is a medical technology company focused on innovative surgical treatments for bunions and midfoot deformities.
When is Treace's presentation at the J.P. Morgan Healthcare Conference?
Treace's presentation is scheduled for Wednesday, January 14, 2026, at approximately 7:30 am PT.
How can I watch the webcast of the fireside chat?
The webcast of the fireside chat will be available on Treace's investor relations website at https://investors.treace.com/.
What medical conditions does Treace's technology address?
Treace’s technology addresses bunions and related midfoot deformities, which affect approximately 67 million Americans.
Where can I find more information about Treace's products?
More information about Treace's products is available on their official website at www.treace.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TMCI Revenue
$TMCI had revenues of $50.2M in Q3 2025. This is an increase of 11.37% from the same period in the prior year.
You can track TMCI financials on Quiver Quantitative's TMCI stock page.
$TMCI Hedge Fund Activity
We have seen 57 institutional investors add shares of $TMCI stock to their portfolio, and 53 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OPALEYE MANAGEMENT INC. added 702,245 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,712,063
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 534,486 shares (+17.2%) to their portfolio in Q3 2025, for an estimated $3,586,401
- KORNITZER CAPITAL MANAGEMENT INC /KS removed 365,393 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,451,787
- FIRST EAGLE INVESTMENT MANAGEMENT, LLC added 330,866 shares (+36.4%) to their portfolio in Q3 2025, for an estimated $2,220,110
- ACUITAS INVESTMENTS, LLC added 301,100 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,020,381
- MORGAN STANLEY removed 259,120 shares (-25.4%) from their portfolio in Q3 2025, for an estimated $1,738,695
- SCHONFELD STRATEGIC ADVISORS LLC removed 239,156 shares (-79.1%) from their portfolio in Q3 2025, for an estimated $1,604,736
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TMCI Analyst Ratings
Wall Street analysts have issued reports on $TMCI in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Underweight" rating on 11/07/2025
To track analyst ratings and price targets for $TMCI, check out Quiver Quantitative's $TMCI forecast page.
$TMCI Price Targets
Multiple analysts have issued price targets for $TMCI recently. We have seen 4 analysts offer price targets for $TMCI in the last 6 months, with a median target of $5.425.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $3.0 on 12/18/2025
- Lilia-Celine Lozada from JP Morgan set a target price of $5.0 on 11/07/2025
- Danielle Antalffy from UBS set a target price of $5.85 on 11/07/2025
- Rick Wise from Stifel set a target price of $6.0 on 08/08/2025
Full Release
PONTE VEDRA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that John T. Treace, Chief Executive Officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, beginning at approximately 7:30 am PT.
A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/ .
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at
www.treace.com
. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty ® 3D Bunion Correction ® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty ® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty ® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System and the SpeedMTP ® MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate ® rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide™ patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com .
To learn more about Treace, connect with us on LinkedIn , X , Facebook and Instagram .
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
[email protected]
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
[email protected]
